Advertisement

Sacral Neuromodulation for Overactive Bladder

  • John R. Michalak
  • Sunchin Kim
  • Joel T. Funk
  • Christian O. Twiss
Chapter

Abstract

Overactive bladder (OAB) is a urologic condition that negatively impacts quality of life. Sacral neuromodulation (SNM) is a safe and effective treatment option that has been studied extensively in patients with severe and refractory OAB. SNM significantly reduces urgency, frequency, and incontinence while also improving quality of life. Although SNM is not currently indicated for the treatment of OAB symptoms due to neurologic disease, recent literature suggests that these patients may also benefit from SNM. Other areas requiring further investigation include reduction of adverse events associated with SNM and the overall cost benefit ratio of SNM.

Keywords

Sacral neuromodulation Overactive bladder Urinary incontinence Urinary urgency Urinary frequency Urge incontinence Quality of life 

Abbreviations

AUA

American Urologic Association

BoNT-A

Botulinum Toxin A

CIC

Clean intermittent catheterization

EAU

European Urologic Association

FDA

Food and drug administration

LUTD

Lower urinary tract dysfunction

LUTS

Lower urinary tract symptoms

MRI

Magnetic resonance imaging

MS

Multiple sclerosis

OAB

Overactive bladder

OMT

Optimal medical therapy

PTNS

Percutaneous tibial nerve stimulation

QAYL

Quality adjusted life years

QoL

Quality of life

SNM

Sacral neuromodulation

References

  1. 1.
    Coyne KS, Sexton CC, Bell JA, Thompson CL, Dmochowski R, Bavendam T, Chen CI, Quentin Clemens J. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol Urodyn. 2013;32:230–7.PubMedCrossRefGoogle Scholar
  2. 2.
    Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36.PubMedGoogle Scholar
  3. 3.
    Reynolds WS, Fowke J, Dmochowski R. The burden of overactive bladder on US Public Health. Curr Bladder Dysfunct Rep. 2016;11(1):8–13.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Comorbidities and personal burden of urgency urinary incontinence: a systematic review. Int J Clin Pract. 2013;67(10):1015–33.PubMedCrossRefGoogle Scholar
  5. 5.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.PubMedCrossRefGoogle Scholar
  6. 6.
    Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen CI, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol. 2014;65(1):79–95.PubMedCrossRefGoogle Scholar
  7. 7.
    Milsom I, Kaplan SA, Coyne KS, Sexton CC, Kopp ZS. Effect of bothersome overactive bladder symptoms on health-related quality of life, anxiety, depression, and treatment seeking in the United States: results from EpiLUTS. Urology. 2012;80(1):90–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Birder L, Andersson KE. Urothelial signaling. Physiol Rev. 2013;93:653–80.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Birder L, de Groat W, Mills I, Morrison J, Thor K, Drake M. Neural control of the lower urinary tract: peripheral and spinal mechanisms. Neurourol Urodyn. 2010;29:128–39.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Andersson KE, McCloskey KD. Lamina propria: the functional center of the bladder? Neurourol Urodyn. 2014;33:9–16.PubMedCrossRefGoogle Scholar
  11. 11.
    Janig W, Morrison JF. Functional properties of spinal visceral afferents supplying abdominal and pelvic organs, with special emphasis on visceral nociception. Prog Brain Res. 1986;67:87–114.PubMedCrossRefGoogle Scholar
  12. 12.
    Habler HJ, Janig W, Koltzenburg M. Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. J Physiol. 1990;425:545–62.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Fall M, Lindstrom S, Mazieres L. A bladder-to-bladder cooling reflex in the cat. J Physiol. 1990;427:281–300.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Juszczak K, Ziomber A, Wyczolkowski M, Thor PJ. Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats. J Physiol Pharmacol. 2009;60:85–91.PubMedGoogle Scholar
  15. 15.
    de Groat WC. A neurologic basis for the overactive bladder. Urology. 1997;50:36–52.PubMedCrossRefGoogle Scholar
  16. 16.
    Brading AF, Turner WH. The unstable bladder: towards a common mechanism. Br J Urol. 1994;73:3–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Brading AF. A myogenic basis for the overactive bladder. Urology. 1997;50:57–67.PubMedCrossRefGoogle Scholar
  18. 18.
    Mills IW, Greenland JE, McMurray G, McCoy R, Ho KM, Noble JG, Brading AF. Studies of the pathophysiology of idiopathic detrusor instability: the physiological properties of the detrusor smooth muscle and its pattern of innervation. J Urol. 2000;163:646–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Drake MJ, Mills IW, Gillespie JI. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet. 2001;358:401–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Coolsaet BL, Van Duyl WA, Van Os-Bossagh P, De Bakker HV. New concepts in relation to urge and detrusor activity. Neurourol Urodyn. 1993;12:463–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Sukhu T, Kennelly MJ, Kurpad R. Sacral neuromodulation in overactive bladder: a review and current perspectives. Res Rep Urol. 2016;8:193–9.PubMedPubMedCentralGoogle Scholar
  22. 22.
    Yoshimura N, de Groat WC. Patch clamp analysis of afferent and efferent neurons that innervated the urinary bladder of the rat. Soc Neurosci Abstr. 1992;18:127.Google Scholar
  23. 23.
    Yoshimura N, de Groat WC. Neural control of the lower urinary tract. Int J Urol. 1997;4:111.PubMedCrossRefGoogle Scholar
  24. 24.
    Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, Das AK, Foster HE Jr, Scarpero HM, Tessier CD, Vasavada SP, American Urological Association. Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction: diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;188(6 Suppl):2455–63.PubMedCrossRefGoogle Scholar
  26. 26.
    Fantl JA, Wyman JF, McClish DK, Harkins SW, Elswick RK, Taylor JR, Hadley EC. Efficacy of bladder training in older women with urinary incontinence. JAMA. 1991;265(5):609–13.PubMedCrossRefGoogle Scholar
  27. 27.
    Jarvis GJ. A controlled trial of bladder drill and drug therapy in the management of detrusor instability. Br J Urol. 1981;53(6):565–6.PubMedCrossRefGoogle Scholar
  28. 28.
    Goode PS, Burgio KL, Locher JL, Umlauf MG, Lloyd LK, Roth DL. Urodynamic changes associated with behavioral and drug treatment of urge incontinence in older women. J Am Geriatr Soc. 2002;50(5):808–16.PubMedCrossRefGoogle Scholar
  29. 29.
    Kaya S, Akbayrak T, Beksac S. Comparison of different treatment protocols in the treatment of idiopathic detrusor overactivity: a randomized controlled trial. Clin Rehabil. 2011;25(4):327–38.PubMedCrossRefGoogle Scholar
  30. 30.
    Arruda RM, Castro RA, Sousa GC, Sartori MG, Baracat EC, Girão MJ. Prospective randomized comparison of oxybutynin, functional electrostimulation, and pelvic floor training for treatment of detrusor overactivity in women. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(8):1055–61.PubMedCrossRefGoogle Scholar
  31. 31.
    Burgio KL, Locher JL, Goode PS, Hardin JM, McDowell BJ, Dombrowski M, Candib D. Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. JAMA. 1998;280(23):1995–2000.PubMedCrossRefGoogle Scholar
  32. 32.
    Song C, Park JT, Heo KO, Lee KS, Choo MS. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci. 2006;21(6):1060–3.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Wyndaele JJ, Goldfischer ER, Morrow JD, Gong J, Tseng LJ, Guan Z, Choo MS. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract. 2009;63(4):560–7.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Zinner N, Noe L, Rasouliyan L, Marshall T, Seifeldin R. Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER. Curr Med Res Opin. 2008;24(6):1583–91.PubMedCrossRefGoogle Scholar
  35. 35.
    Zinner N, Kobashi KC, Ebinger U, Viegas A, Egermark M, Quebe-Fehling E, Koochaki P. Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy. Int J Clin Pract. 2008;62(11):1664–74.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Hussein M, Fanning K, Trocio JN, Brubaker L. Patient-reported reasons for discontinuing overactive bladder medication. BJU Int. 2010;105(9):1276–82.PubMedCrossRefGoogle Scholar
  37. 37.
    Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.PubMedCrossRefGoogle Scholar
  38. 38.
    Dmochowski RR, Sand PK, Zinner NR, Staskin DR. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008;71(3):449–54.PubMedCrossRefGoogle Scholar
  39. 39.
    Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stolzel M, Martin N, Gunther A, Van Kerrebroeck P. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82(2):313–20.PubMedCrossRefGoogle Scholar
  40. 40.
    Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189(4):1388–95.PubMedCrossRefGoogle Scholar
  41. 41.
    Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, Dorrepaal C, Martin N. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305.PubMedCrossRefGoogle Scholar
  42. 42.
    Warren K, Burden H, Abrams P. Mirabegron in overactive bladder patients: efficacy review and update on drug safety. Ther Adv Drug Saf. 2016;7(5):204–16.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Perk S, Wielage RC, Campbell NL, Klein TM, Perkins A, Posta LM, Yuran T, Klein RW, Ng DB. Estimated budget impact of increased use of mirabegron, a novel treatment for overactive bladder. J Manag Care Spec Pharm. 2016;22(9):1072–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, Barber MD, Menefee S, Schaffer J, Weber AM, Wei J, Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol. 2008;180(1):217–22.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;181(6):2608–15.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Kuo HC. Bladder base/trigone injection is safe and as effective as bladder body injection of onabotulinumtoxinA for idiopathic detrusor overactivity refractory to antimuscarinics. Neurourol Urodyn. 2011;30(7):1242–8.PubMedGoogle Scholar
  47. 47.
    Orasanu B, Mahajan S. The use of botulinum toxin for the treatment of overactive bladder syndrome. Indian J Urol. 2013;29(1):2–11.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Kuo Y, Kuo H. Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis—different mechanisms of action of Botox on bladder dysfunction? Toxins (Basel). 2016;8(3).PubMedCentralCrossRefGoogle Scholar
  49. 49.
    Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, Siegel SW, Tate SB, Jarnagin BK, Rosenblatt PL, Feagins BA. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–61.PubMedCrossRefGoogle Scholar
  50. 50.
    Sancaktar M, Ceyhan ST, Akyol I, Muhcu M, Alanbay I, Mutlu Ercan C, Atay V. The outcome of adding peripheral neuromodulation (Stoller afferent neuro-stimulation) to anti-muscarinic therapy in women with severe overactive bladder. Gynecol Endocrinol. 2010;26(10):729–32.PubMedCrossRefGoogle Scholar
  51. 51.
    Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: a systematic review and meta-analysis. Neurourol Urodyn. 2012;31(8):1206–16.PubMedCrossRefGoogle Scholar
  52. 52.
    Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology. 2000;4(56):87–91.CrossRefGoogle Scholar
  53. 53.
    Everaert K, Kerckhaert W, Caluwaerts H. A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation. Eur Urol. 2004;45:649–54.PubMedCrossRefGoogle Scholar
  54. 54.
    National Guideline Clearinghouse (NGC). Guideline summary: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. In: National Guideline Clearinghouse (NGC) [Web site]. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ); 2014 May 01. [cited 2016 Dec 01]. https://www.guideline.gov
  55. 55.
    Tanagho EA, Schmidt RA. Bladder pacemaker: scientific basis and clinical future. Urology. 1982;20(6):614–9.PubMedCrossRefGoogle Scholar
  56. 56.
    Schmidt RA, Jonas U, Oleson KA, Jankgnegt RA, Hassouna MM, Siegel SW, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol. 1999;162(2):352–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Scheepens WA, Weil EH, van Koeveringe GA, Rohrmann D, Hedlund HE, Schurch B, et al. Buttock placement of the implantable pulse generator: a new implantation technique for sacralneuromodulation—a multicenter study. Eur Urol. 2001;40(4):434–8.CrossRefPubMedGoogle Scholar
  58. 58.
    Hetzer FH. Fifteen years of sacral nerve stimulation: from an open procedure to a minimally invasive technique. Color Dis. 2011;13(2):1–4.CrossRefGoogle Scholar
  59. 59.
    Spinelli M, Giardiello G, Arduini A, Van den Hombergh U. New percutaneous technique of sacral nerve stimulation has high initial success rate: preliminary results. Eur Urol. 2003;43(1):70–4.CrossRefPubMedGoogle Scholar
  60. 60.
    Hijaz A, Vasavada S. Complications and troubleshooting of sacral neuromodulation therapy. Urol Clin North Am. 2005;32:65–9.CrossRefPubMedGoogle Scholar
  61. 61.
    Siddiqui NY, JM W, Amundsen CL. Efficacy and adverse events of sacral nerve stimulation for overactive bladder: a systematic review. Neurourol Urodyn. 2010;29(Suppl 1):S18–23.PubMedCrossRefGoogle Scholar
  62. 62.
    Peeters K, Sahai A, De Ridder D, Van Der Aa F. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int. 2014;113(5):789–94.PubMedCrossRefGoogle Scholar
  63. 63.
    Bladder and Bowel Community. Sacral Nerve Stimulation (Sacral Neuromodulation Therapy); [cited 2017 Jan 22]. https://www.bladderandbowelfoundation.org.
  64. 64.
    Amundsen CL, Romero AA, Jamison MG, Webster GD. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology. 2005;66(4):746–50.PubMedCrossRefGoogle Scholar
  65. 65.
    Elkelini MS, Hassouna MM. Safety of MRI at 1.5Tesla in patients with implanted sacral nerve neurostimulator. Eur Urol. 2006;50(2):311–6.PubMedCrossRefGoogle Scholar
  66. 66.
    Chermansky CJ, Krlin RM, Holley TD, Woo HH, Winters JC. Magnetic resonance imaging following InterStim®: an institutional experience with imaging safety and patient satisfaction. Neurourol Urodyn. 2011;30(8):1486–8.PubMedCrossRefGoogle Scholar
  67. 67.
    Alsyouf M, Keheila M, Marinone M. Magnetic resonance imaging of the ankle performed on an InterStim patient. Can J Urol. 2016;23(1):8168–70.PubMedGoogle Scholar
  68. 68.
    MRI guidelines for InterStim Therapy Neurostimulation Systems. 1st ed. Medtronic, 2017; [2017 Jan 15]. https://professional.medtronic.com.
  69. 69.
    Yaiesh SM, Al-Terki AE, Al-Shaiji TF. Safety of sacral nerve stimulation in pregnancy: a literature review. Neuromodulation. 2016;19:770–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Noblett K, Benson K, Kreder K. Detailed analysis of adverse events and surgical interventions in a large prospective trial of sacralneuromodulation therapy for overactive bladder patients. Neurourol Urodyn.  https://doi.org/10.1002/nau.23076. [Epub ahead of print].
  71. 71.
    Marcelissen TA, Leong RK, de Bie RA. Long-term results of sacral neuromodulation with the tined lead procedure. J Urol. 2010;184:1997–2000.PubMedCrossRefGoogle Scholar
  72. 72.
    Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh Urology. 12th ed. Philadelphia, PA: Elsevier; 2016.Google Scholar
  73. 73.
    Groenendijk PM, Lycklama à Nyeholt AA, Heesakkers JP, van Kerrebroeck PE, Hassouna MM, Gajewski JB. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int. 2008;101(3):325–9.PubMedCrossRefGoogle Scholar
  74. 74.
    Aboseif S, Tamaddon K, Chalfin S, Freedman S, Kaptein J. Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction. Urology. 2002;60(1):52–6.PubMedCrossRefGoogle Scholar
  75. 75.
    Hassouna MM, Siegel SW, Nyeholt AA. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000;163:1849–54.PubMedCrossRefGoogle Scholar
  76. 76.
    Weil EH, Ruiz-Cerdá JL, Eerdmans PH. Sacral root neuromodulation in the treatment of refractory urinary urge incontinence: a prospective randomized clinical trial. Eur Urol. 2000;37(2):161–71.PubMedCrossRefGoogle Scholar
  77. 77.
    van Kerrebroeck EV, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective worldwide clinical study. J Urol. 2007;178:2029–34.CrossRefPubMedGoogle Scholar
  78. 78.
    Groen J, Blok BF, Bosch JL. Sacral neuromodulation as treatment for refractory idiopathic urge urinary incontinence: 5-year results of a longitudinal study in 60 women. J Urol. 2011;186(3):954–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Cardarelli S, D'Elia C, Cerruto MA, Curti P, Ostardo E, Signorello D, et al. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project. Urologia. 2012;79(2):90–6.PubMedCrossRefGoogle Scholar
  80. 80.
    Moon KH, Han JY, Kim JH, Lee HN, Lee KS, Lee JG, SJ O, Yoon HN, Choo MS. Prospective trial of sacral neuromodulation for refractory overactive bladder syndrome in Korean patients. Low Urin Tract Symptoms. 2013;6(3):175–9.PubMedCrossRefGoogle Scholar
  81. 81.
    Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30.PubMedCrossRefGoogle Scholar
  82. 82.
    Leong RK, Marcelissen TA, Nieman FH. Satisfaction and patient experience with sacral neuromodulation: results of a single center sample survey. J Urol. 2011;185(2):588–92.PubMedCrossRefGoogle Scholar
  83. 83.
    Kessler TM, La Framboise D, Trelle S, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58:865–74.PubMedCrossRefGoogle Scholar
  84. 84.
    Tanagho EA, Schmidt RA, Orvis BR. Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. J Urol. 1989;142:340–5.PubMedCrossRefGoogle Scholar
  85. 85.
    Lombardi G, Del Popolo G. Clinical outcome of sacral neuromodulation in incomplete spinal cord injured patients suffering from neurogenic lower urinary tract symptoms. Spinal Cord. 2009;47(6):486–91.PubMedCrossRefGoogle Scholar
  86. 86.
    Lombardi G, Nelli F, Mencarini M, Del Popolo G. Clinical concomitant benefits on pelvic floor dysfunctions after sacral neuromodulation in patients with incomplete spinal cord injury. Spinal Cord. 2011;49:629–36.PubMedCrossRefGoogle Scholar
  87. 87.
    Chen G, Liao L. Sacral neuromodulation for neurogenic bladder and bowel dysfunction with multiple symptoms secondary to spinal cord disease. Spinal Cord. 2015;53:204–8.CrossRefGoogle Scholar
  88. 88.
    Wöllner J, Krebs J, Pannek J. Sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction. Spinal Cord. 2016;54(2):137–40.PubMedCrossRefGoogle Scholar
  89. 89.
    Minardi D, Muzzonigro G. Sacral neuromodulation in patients with multiple sclerosis. World J Urol. 2012;30:123–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Engeler DS, Meyer D, Abt D. Sacral neuromodulation for the treatment of neurogenic lower urinary tract dysfunction caused by multiple sclerosis: a single-centre prospective series. BMC Urol. 2015;15:105.PubMedPubMedCentralCrossRefGoogle Scholar
  91. 91.
    Puccini F, Bhide A, Elneil S, Digesu GA. Sacral neuromodulation: an effective treatment for lower urinary tract symptoms in multiple sclerosis. Int Urogynecol J. 2016;27(3):347–54.PubMedCrossRefGoogle Scholar
  92. 92.
    Wallace PA, Lane FL, Noblett KL. Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol. 2007;197(1):96.e1–5.CrossRefGoogle Scholar
  93. 93.
    Peters KM, Kandagatla P, Killinger KA, Wolfert C, Boura JA. Clinical outcomes of sacral neuromodulation in patients with neurologic conditions. Urology. 2013;81(4):738–43.PubMedCrossRefGoogle Scholar
  94. 94.
    Al-zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol. 2011;185:981–6.CrossRefPubMedGoogle Scholar
  95. 95.
    Spinelli M, Weil E, Ostardo E. New tined lead electrode in sacral neuromodulation: experience from a multicentre European study. World J Urol. 2005;23(3):225–9.PubMedCrossRefGoogle Scholar
  96. 96.
    Peters KM, Carey JM, Konstandt DB. Sacral neuromodulation for the treatment of refractory interstitial cystitis: outcomes based on technique. Int Urogynecol J Pelvic Floor Dysfunct. 2003;14:223–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Scheepens WA, Van Koeveringe GA, De Bie RA, et al. Long-term efficacy and safety results of the two-stage implantation technique in sacral neuromodulation. BJU Int. 2002;90:840–5.PubMedCrossRefGoogle Scholar
  98. 98.
  99. 99.
    Benninghoff D. Anatomy. Urban & Fischer Verlag: München; 2003.Google Scholar
  100. 100.
    Amend B, Matzel KE, Abrams P, de Groat WC, Sievert KD. How does neuromodulation work. Neurourol Urodyn. 2011;30(5):762–5.PubMedCrossRefGoogle Scholar
  101. 101.
    Swinn MJ, Schott GD, Oliver SE. Leg pain after sacral neuromodulation: anatomical considerations. BJU Int. 1999;84:1113–5.PubMedCrossRefGoogle Scholar
  102. 102.
    Cohen BL, Tunuguntla HS, Gousse A. Predictors of success for first stage neuromodulation: motor versus sensory response. J Urol. 2006;175:2178–80.PubMedCrossRefGoogle Scholar
  103. 103.
    Govaert B, Melenhorst J, Van Gemert WG, Baeten CG. Can sensory and/or motor reactions during percutaneous nerve evaluation predict outcome of sacral nerve modulation? Dis Colon Rectum. 2009;52:1423–6.PubMedCrossRefGoogle Scholar
  104. 104.
    Candiotti KA, Bergese SD, Bokesch PM, Feldman MA, Wisemandle W, Bekker AY. Monitored anesthesia care with dexmedetomidine: a prospective, randomized, double-blind, multicenter trial. MAC Study Group. Anesth Analg. 2010;110(1):47–56.PubMedCrossRefGoogle Scholar
  105. 105.
    Jacobs SA, Lane FL, Osann KE, Noblett KL. Randomized prospective crossover study of InterStim lead wire placement with curved versus straight stylet. Neurourol Urodyn. 2014;33(5):488–92.PubMedCrossRefGoogle Scholar
  106. 106.
    Onukwugha E, Zuckerman I, et al. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care. 2009;15(4 Suppl):S90–7.PubMedGoogle Scholar
  107. 107.
    Aboseif SR, Kim DH, Rieder JM. Sacral neuromodulation: cost considerations and clinical benefits. Urology. 2007;70(6):1069–74.PubMedCrossRefGoogle Scholar
  108. 108.
    Siddiqui NY, Amundsen CL, Visco AG, Myers ER, Wu JM. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence. J Urol. 2009;182(6):2799–804.PubMedCrossRefGoogle Scholar
  109. 109.
    Autiero SW, Hallas N, Betts CD, Ockrim JL. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int. 2015;116(6):945–54.PubMedCrossRefGoogle Scholar
  110. 110.
    Arlandis S, Castro D, Errando C, Fernández E, Jiménez M, González P, et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Value Health. 2011;14(2):219–28.PubMedCrossRefGoogle Scholar
  111. 111.
    Bertapelle MP, Vottero M, Popolo GD, Mencarini M, Ostardo E, Spinelli M, et al. Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System. World J Urol. 2015;33(8):1109–17.PubMedCrossRefGoogle Scholar
  112. 112.
    Hassouna MM, Sadri H. Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective. Can Urol Assoc J. 2015;9(7–8):242–7.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • John R. Michalak
    • 1
  • Sunchin Kim
    • 1
  • Joel T. Funk
    • 1
  • Christian O. Twiss
    • 1
  1. 1.Division of Urology, Department of SurgeryUniversity of Arizona College of MedicineTucsonUSA

Personalised recommendations